Emergent BioSolutions (NYSE:EBS) Rating Lowered to Hold at StockNews.com

StockNews.com downgraded shares of Emergent BioSolutions (NYSE:EBS) from a buy rating to a hold rating in a research report sent to investors on Friday morning.

A number of other brokerages have also recently issued reports on EBS. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Emergent BioSolutions in a research note on Tuesday, January 21st. Benchmark increased their price target on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, November 7th.

Emergent BioSolutions Trading Up 1.2 %

Shares of NYSE EBS opened at $11.61 on Friday. The stock has a market cap of $629.19 million, a P/E ratio of -2.83 and a beta of 1.60. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47. Emergent BioSolutions has a 1 year low of $1.42 and a 1 year high of $15.10. The firm has a 50-day moving average of $9.39 and a 200 day moving average of $9.31.

Emergent BioSolutions (NYSE:EBS) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $1.37 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.88. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. The firm had revenue of $293.80 million for the quarter, compared to analysts’ expectations of $328.72 million. During the same period in the previous year, the firm posted ($1.44) EPS. As a group, sell-side analysts expect that Emergent BioSolutions will post -0.63 EPS for the current fiscal year.

Hedge Funds Weigh In On Emergent BioSolutions

A number of hedge funds have recently bought and sold shares of the business. Jacobs Levy Equity Management Inc. bought a new stake in shares of Emergent BioSolutions in the third quarter worth approximately $1,547,000. Oak Hill Advisors LP purchased a new stake in Emergent BioSolutions during the 3rd quarter valued at $9,296,000. Assenagon Asset Management S.A. lifted its holdings in shares of Emergent BioSolutions by 74.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company’s stock valued at $6,192,000 after buying an additional 316,700 shares during the period. Barclays PLC boosted its stake in shares of Emergent BioSolutions by 361.6% in the 3rd quarter. Barclays PLC now owns 39,308 shares of the biopharmaceutical company’s stock worth $329,000 after buying an additional 30,792 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Emergent BioSolutions by 4.6% in the third quarter. Geode Capital Management LLC now owns 581,958 shares of the biopharmaceutical company’s stock worth $4,861,000 after acquiring an additional 25,776 shares during the period. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.